EP2714713A1 - Purification of antibodies - Google Patents

Purification of antibodies

Info

Publication number
EP2714713A1
EP2714713A1 EP12790188.2A EP12790188A EP2714713A1 EP 2714713 A1 EP2714713 A1 EP 2714713A1 EP 12790188 A EP12790188 A EP 12790188A EP 2714713 A1 EP2714713 A1 EP 2714713A1
Authority
EP
European Patent Office
Prior art keywords
buffer
exchange chromatography
process according
antibody
wash
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP12790188.2A
Other languages
German (de)
French (fr)
Other versions
EP2714713B1 (en
EP2714713A4 (en
Inventor
Kishore Jahagirdar
Neeru Gupta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dr Reddys Laboratories Ltd
Original Assignee
Dr Reddys Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dr Reddys Laboratories Ltd filed Critical Dr Reddys Laboratories Ltd
Publication of EP2714713A1 publication Critical patent/EP2714713A1/en
Publication of EP2714713A4 publication Critical patent/EP2714713A4/en
Application granted granted Critical
Publication of EP2714713B1 publication Critical patent/EP2714713B1/en
Not-in-force legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20

Definitions

  • the present invention relates to a method of purification of antibodies comprising a cation exchange chromatography step.
  • Therapeutic proteins are primarily products of recombinant DNA technology, i.e., cloning and expression of a heterologus gene in prokaryotic or eukaryotic systems.
  • proteins expressed by recombinant DNA methods are typically associated with impurities such as host cell proteins (HCP), host cell DNA (HCD), viruses, etc.
  • HCP host cell proteins
  • HCD host cell DNA
  • viruses etc.
  • HCP host cell proteins
  • HCD host cell DNA
  • heterogeneity in the expression of the desired protein in the form of charged variants (typically acidic, lower pi variants and basic, higher pi variants).
  • multimeric proteins, such as antibodies have a higher tendency to aggregate, contributing to significantly increased impurity levels.
  • Antibodies constitute one of the most important classes of therapeutic proteins, especially in the areas of oncology, arthritis and other chronic diseases.
  • the prior art discloses various methods for purification of crude or partially purified antibodies.
  • WO 89/05157 teaches purification of immunoglobulins by cation- exchange chromatography using varying pH and salt concentrations in the wash and elution steps.
  • WO 2004/024866 describes a method of purifying a polypeptide by ion exchange chromatography in which a gradient wash with differing salt concentrations is used to resolve the polypeptide.
  • WO 1999/057134 describes the use of ion exchange chromatography for purification of polypeptides by varying conductivity and/or pH.
  • US 51 10913 claims purification of murine antibodies using low pH and at least three different pH conditions in the ion-exchange chromatographic step.
  • the principle object of the present invention is to provide an improved method for obtaining antibody preparations that avoids use of low pH conditions and significantly reduces alterations in pH during a
  • the present invention describes a process for the purification of antibodies from a mixture of impurities using cation exchange chromatography wherein the pH of a first wash buffer is similar to the pH of the load buffer, and pH of a second wash buffer is similar to the pH of the elution buffer.
  • Fig. 1 is an illustration of a chromatogram from the procedure as described in Example 1 .
  • the line marked “Cond” represents the increase in conductivity in mS/cm.
  • Peak A represents the eluate obtained from protein A chromatography resin.
  • Fig. 2 is an illustration of a chromatogram from the procedure as described in Example 2.
  • Peak A and B represent the eluate obtained from cation exchange chromatography.
  • Peak A and B are charge variants of the anti-CD20 antibody.
  • Fig. 3 is an illustration of a chromatogram from the procedure as described in Example 2. The consistency of elution in multiple runs is shown.
  • Fig. 4 is an illustration of a chromatogram from the procedure as described in Example 3.
  • Figure represents the flow- through fraction of the anion exchange chromatography.
  • the present invention describes a process for purification of antibodies by cation exchange chromatography.
  • the chromatographic conditions require minimal pH adjustments during load/wash/elution steps.
  • the process described in the present invention also avoids use of low pH buffers.
  • the conditions described in the present invention results in effective separation of charged variants, as well as removal of impurities such as HCP, aggregates and Protein A leachates and an optimum yield of the desired antibody.
  • antibody refers to immunoglobulins and can be isolated from various sources, such as murine, human, recombinant etc. In its broadest sense it includes monoclonal antibodies, polyclonal antibodies,
  • antibodies chimeric, humanized or pegylated antibodies, isotypes, allotypes and alleles of immunoglobulin genes and fusion proteins, which contain an
  • impurities refers to a material that is different from the desired polypeptide. They may be nucleic acids such as host cell DNA, host cell proteins, variants of the desired polypeptide, another polypeptide, endotoxin etc.
  • low pH refers to a pH of less than 6.0
  • load buffer refers to the buffer that is used to load the composition comprising the antibody of interest and one or more impurities onto the ion exchange support.
  • wash buffer refers to a buffer that is used to wash or re-equilibrate the ion exchange support, or to elute one or more impurities from the ion exchange support, prior to elution of the antibody of interest.
  • the "elution buffer” is used to elute the antibody of interest from the ion exchange support.
  • the invention provides a method of the purification of antibodies comprising,
  • the pH of the second wash buffer is less than the pH of the first wash buffer.
  • the invention provides a method for the purification of antibodies comprising,
  • a protein-A chromatography may precede the cation exchange chromatography.
  • another ion-exchange chromatography or a hydrophobic interaction chromatography may precede or follow the cation exchange
  • inventions mentioned herein may optionally include one or more tangential flow filtration, concentration, diafiltration or ultra filtration steps.
  • inventions mentioned herein optionally include one or more viral inactivation steps or sterile filtration or nano filtration steps.
  • the embodiments mentioned herein may include one or more neutralization steps.
  • the protein A chromatographic resin used may be any protein A or variant or a functional fragment thereof coupled to any chromatographic support.
  • the protein A resin is MabselectTM (GE-Healthcare Life sciences), an affinity matrix with recombinant Protein-A ligand.
  • the resin is made of highly cross- linked agarose matrix.
  • Cation exchange chromatographic step mentioned in the embodiments may be carried out using any weak or strong cation exchange chromatographic resin or a membrane, which could function as a weak or a strong cation exchanger.
  • cation exchange support include a resin, but are not limited to, those having a sulfonate based group e.g., MonoS, MiniS, Source 15S and 30S, SP Sepharose Fast Flow, SP Sepharose High Performance from GE Healthcare, Toyopearl SP-650S and SP-650M from Tosoh, S-Ceramic Hyper D, from Pall Corporation or a carboxymethyl based group e.g., CM Sepharose Fast Flow from GE Healthcare, Macro-Prep CM from BioRad, CM-Ceramic Hyper D, from Pall
  • CM-650S Toyopearl CM-650S, CM-650M and CM-650C from Tosoh.
  • the support could be a monolithic column, disk or tubular, that performs the function of a cation exchanger.
  • a strong cation exchange resin such as SP-Sepharose ® (GE Healthcare Life Sciences) is used. This resin is made using a highly cross-linked, 6 % agarose matrix attached to a sulfopropyl functional group.
  • Anion exchange chromatography mentioned in the embodiments may be carried out using any weak or strong anion exchange chromatographic resin or a membrane which could function as a weak or a strong anion exchanger.
  • anion exchange resins include, but are not limited to, DEAE cellulose, Poros PI 20, PI 50, HQ 10, HQ 20, HQ 50, D 50 from Applied Biosystems, MonoQ, MiniQ, Source 15Q and 3OQ, Q, DEAE and ANX Sepharose Fast Flow, Q Sepharose high Performance, QAE SEPHADEX and FAST Q SEPHAROSE from GE Healthcare, Macro-Prep DEAE and Macro-Prep High Q from Biorad, Q-Ceramic Hyper D, DEAE-Ceramic Hyper D, from Pall Corporation.
  • a strong anion exchange resin such as Q- Sepharose Fast Flow ® (GE Healthcare Life Sciences) is used.
  • This resin is made of highly cross-linked, 6 % agarose matrix attached to -O-CH 2 CHOHCH2OCH2CHOHCH 2 N + (CH3)3 functional group.
  • buffering agents used in the buffer solutions include, but are not limited to, TRIS, phosphate, citrate, acetate, succinate, MES, MOPS, or ammonium and their salts or derivatives thereof.
  • An anti-CD20 antibody was cloned and expressed in a CHO cell line as described in U.S. Patent No. 7,381 ,560, which is incorporated herein by reference.
  • the cell culture broth containing the expressed antibody was harvested, clarified and subjected to protein A affinity chromatography as described below.
  • the clarified cell culture broth was loaded onto a protein A chromatography column (Mabselect, VL44x250, 205 mL) that was pre-equilibrated with Tris buffer solution (pH 7.0). The column was then washed with equilibration buffer. This was followed by a wash with Tris buffer (pH 7.0) with higher conductivity and a final wash with citrate buffer at pH 5. The bound antibody was eluted using citrate buffer, pH 2.5 - 3.5.
  • the eluate obtained from the protein A chromatography procedure described in Example 1 was loaded onto a cation exchange resin (SP Sepharose, VL44x250, 304 mL) pre-equilibrated with Tris buffer (pH 7.5) at a conductivity of 3.0 to 6.0 mS/cm. This was followed by washing the resin with a wash buffer of Tris buffer (pH 7.5) at a conductivity of 3.0 to 6.0 mS/cm. A second wash step was performed with wash buffer consisting of citrate buffer, pH 6.5, at a conductivity of 3.0 to 6.0. The bound antibody was eluted using a buffer of citrate buffer, pH 6.5 at conductivity between 9-12 mS/cm.
  • SP Sepharose SP Sepharose, VL44x250, 304 mL
  • the eluate obtained from the cation exchange chromatography procedure described in Example 2 was loaded onto an anion exchange resin (Q-Sepharose FF, VL32x250, 80 mL) pre-equilibrated with a Tris buffer (pH 7.5) equilibration buffer. This was followed by a post load wash with equilibration buffer and the load and wash flow-through was collected.
  • anion exchange resin Q-Sepharose FF, VL32x250, 80 mL

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

The invention provides a method of purification of antibodies using chromatographic technique. The method involves the use of cation -exchange chromatography for the purification of the antibody. The purified antibody can be used as a therapeutic composition.

Description

PURIFICATION OF ANTIBODIES
FIELD OF THE INVENTION
The present invention relates to a method of purification of antibodies comprising a cation exchange chromatography step.
BACKGROUND OF THE INVENTION
Large-scale purification of proteins remains a significant challenge in the biopharmaceutical industry as efficient and cost-effective methods are required to achieve desired yields and purity levels. Therapeutic proteins are primarily products of recombinant DNA technology, i.e., cloning and expression of a heterologus gene in prokaryotic or eukaryotic systems. However, proteins expressed by recombinant DNA methods are typically associated with impurities such as host cell proteins (HCP), host cell DNA (HCD), viruses, etc. Also, there is significant heterogeneity in the expression of the desired protein, in the form of charged variants (typically acidic, lower pi variants and basic, higher pi variants). Further, multimeric proteins, such as antibodies, have a higher tendency to aggregate, contributing to significantly increased impurity levels.
The presence of these impurities, including aggregates and undesirable charged variants, is a potential health risk, and hence their removal from a final product is a regulatory requirement. Thus drug regulatory agencies such as United States Food and Drug administration (FDA) require that biopharmaceuticals be free from impurities, both product related (aggregates or degradation products) and process related (media components, HCP, DNA, chromatographic media used in purification, endotoxins, viruses, etc). See, Office of Biologies Research and Review, Food and Drug Administration, Points to consider in the production and testing of new drugs and biologicals produced by recombinant DNA technology (Draft), 1985. Thus, elimination of impurities from a final product is mandatory and poses a significant challenge in the development of methods for the purification of therapeutic proteins.
Antibodies constitute one of the most important classes of therapeutic proteins, especially in the areas of oncology, arthritis and other chronic diseases. The prior art discloses various methods for purification of crude or partially purified antibodies. WO 89/05157 teaches purification of immunoglobulins by cation- exchange chromatography using varying pH and salt concentrations in the wash and elution steps. WO 2004/024866 describes a method of purifying a polypeptide by ion exchange chromatography in which a gradient wash with differing salt concentrations is used to resolve the polypeptide. WO 1999/057134 describes the use of ion exchange chromatography for purification of polypeptides by varying conductivity and/or pH. US 51 10913 claims purification of murine antibodies using low pH and at least three different pH conditions in the ion-exchange chromatographic step.
However the prior art typically describe the use of low pH wash conditions that may be accompanied by frequent and significant change in pH conditions during load/wash/elution steps. Such frequent alterations of pH conditions during
chromatography may result in considerable reduction of antibody yield and, further, may decrease the stability of the antibody. Moreover frequent pH changes during chromatography pose difficulties in scale up.
Given the cumbersome nature of the conditions described in the prior art, alternative methods for purification of antibodies that alleviate some of the difficulties described above is desirable. The principle object of the present invention is to provide an improved method for obtaining antibody preparations that avoids use of low pH conditions and significantly reduces alterations in pH during a
chromatographic step resulting in effective separation of charge variants, increased purity and recovery of the desired antibody.
SUMMARY OF THE INVENTION
The present invention describes a process for the purification of antibodies from a mixture of impurities using cation exchange chromatography wherein the pH of a first wash buffer is similar to the pH of the load buffer, and pH of a second wash buffer is similar to the pH of the elution buffer.
BRIEF DESCRIPTION OF THE DRAWINGS
Fig. 1 is an illustration of a chromatogram from the procedure as described in Example 1 . The line marked "Cond" represents the increase in conductivity in mS/cm. Peak A, represents the eluate obtained from protein A chromatography resin. Fig. 2 is an illustration of a chromatogram from the procedure as described in Example 2. Peak A and B represent the eluate obtained from cation exchange chromatography. Peak A and B are charge variants of the anti-CD20 antibody.
Fig. 3 is an illustration of a chromatogram from the procedure as described in Example 2. The consistency of elution in multiple runs is shown.
Fig. 4 is an illustration of a chromatogram from the procedure as described in Example 3. Figure represents the flow- through fraction of the anion exchange chromatography. DETAILED DESCRIPTION OF THE INVENTION
The present invention describes a process for purification of antibodies by cation exchange chromatography. The chromatographic conditions require minimal pH adjustments during load/wash/elution steps. The process described in the present invention also avoids use of low pH buffers. The conditions described in the present invention results in effective separation of charged variants, as well as removal of impurities such as HCP, aggregates and Protein A leachates and an optimum yield of the desired antibody.
The term "antibody" as used herein refers to immunoglobulins and can be isolated from various sources, such as murine, human, recombinant etc. In its broadest sense it includes monoclonal antibodies, polyclonal antibodies,
multispecific antibodies and antibody fragments. It also includes truncated
antibodies, chimeric, humanized or pegylated antibodies, isotypes, allotypes and alleles of immunoglobulin genes and fusion proteins, which contain an
immunoglobulin moiety.
The term "impurities" as used herein refers to a material that is different from the desired polypeptide. They may be nucleic acids such as host cell DNA, host cell proteins, variants of the desired polypeptide, another polypeptide, endotoxin etc.
The term "low pH" as used herein refers to a pH of less than 6.0
The term "load buffer" as used herein refers to the buffer that is used to load the composition comprising the antibody of interest and one or more impurities onto the ion exchange support.
The term "wash buffer" as used herein refers to a buffer that is used to wash or re-equilibrate the ion exchange support, or to elute one or more impurities from the ion exchange support, prior to elution of the antibody of interest. The "elution buffer" is used to elute the antibody of interest from the ion exchange support.
In an embodiment, the invention provides a method of the purification of antibodies comprising,
a) Loading the antibody containing solution onto a cation exchange support at a particular pH
b) Washing the support with a first wash buffer at a pH similar to the pH of the load buffer
c) Washing the support with a second wash buffer at a second pH
d) Eluting the antibody from the support using an elution buffer at a pH similar to the second wash buffer,
wherein the pH of the two wash buffers are greater than 6.
In an embodiment, the pH of the second wash buffer is less than the pH of the first wash buffer.
In another embodiment, the invention provides a method for the purification of antibodies comprising,
a) Loading the antibody containing solution onto a cation exchange support with a buffer of pH value from about pH 6.0 to about pH 8.0
b) Washing the support with a wash buffer of pH value from about pH 6.0 to about pH 8.0
c) Washing the support with a second wash buffer of pH about 6.5
d) Eluting the antibody from the support using an elution buffer of pH about 6.5 In an embodiment, a protein-A chromatography, may precede the cation exchange chromatography.
In an embodiment, another ion-exchange chromatography or a hydrophobic interaction chromatography may precede or follow the cation exchange
chromatography.
The embodiments mentioned herein may optionally include one or more tangential flow filtration, concentration, diafiltration or ultra filtration steps.
The embodiments mentioned herein optionally include one or more viral inactivation steps or sterile filtration or nano filtration steps.
The embodiments mentioned herein may include one or more neutralization steps. The protein A chromatographic resin used may be any protein A or variant or a functional fragment thereof coupled to any chromatographic support. In
embodiments, the protein A resin is Mabselect™ (GE-Healthcare Life sciences), an affinity matrix with recombinant Protein-A ligand. The resin is made of highly cross- linked agarose matrix.
Cation exchange chromatographic step mentioned in the embodiments may be carried out using any weak or strong cation exchange chromatographic resin or a membrane, which could function as a weak or a strong cation exchanger.
Commercially available cation exchange support include a resin, but are not limited to, those having a sulfonate based group e.g., MonoS, MiniS, Source 15S and 30S, SP Sepharose Fast Flow, SP Sepharose High Performance from GE Healthcare, Toyopearl SP-650S and SP-650M from Tosoh, S-Ceramic Hyper D, from Pall Corporation or a carboxymethyl based group e.g., CM Sepharose Fast Flow from GE Healthcare, Macro-Prep CM from BioRad, CM-Ceramic Hyper D, from Pall
Corporation, Toyopearl CM-650S, CM-650M and CM-650C from Tosoh.
Alternatively, the support could be a monolithic column, disk or tubular, that performs the function of a cation exchanger. In embodiments of the invention, a strong cation exchange resin, such as SP-Sepharose® (GE Healthcare Life Sciences) is used. This resin is made using a highly cross-linked, 6 % agarose matrix attached to a sulfopropyl functional group.
Anion exchange chromatography mentioned in the embodiments may be carried out using any weak or strong anion exchange chromatographic resin or a membrane which could function as a weak or a strong anion exchanger.
Commercially available anion exchange resins include, but are not limited to, DEAE cellulose, Poros PI 20, PI 50, HQ 10, HQ 20, HQ 50, D 50 from Applied Biosystems, MonoQ, MiniQ, Source 15Q and 3OQ, Q, DEAE and ANX Sepharose Fast Flow, Q Sepharose high Performance, QAE SEPHADEX and FAST Q SEPHAROSE from GE Healthcare, Macro-Prep DEAE and Macro-Prep High Q from Biorad, Q-Ceramic Hyper D, DEAE-Ceramic Hyper D, from Pall Corporation. In embodiments of the invention, a strong anion exchange resin, such as Q- Sepharose Fast Flow® (GE Healthcare Life Sciences) is used. This resin is made of highly cross-linked, 6 % agarose matrix attached to -O-CH2CHOHCH2OCH2CHOHCH2N+(CH3)3 functional group. Examples of buffering agents used in the buffer solutions include, but are not limited to, TRIS, phosphate, citrate, acetate, succinate, MES, MOPS, or ammonium and their salts or derivatives thereof.
The invention is more fully understood by reference to the following examples. These examples should not, however, be construed as limiting the scope of the invention.
EXAMPLE 1
Protein A chromatography
An anti-CD20 antibody was cloned and expressed in a CHO cell line as described in U.S. Patent No. 7,381 ,560, which is incorporated herein by reference. The cell culture broth containing the expressed antibody was harvested, clarified and subjected to protein A affinity chromatography as described below.
The clarified cell culture broth was loaded onto a protein A chromatography column (Mabselect, VL44x250, 205 mL) that was pre-equilibrated with Tris buffer solution (pH 7.0). The column was then washed with equilibration buffer. This was followed by a wash with Tris buffer (pH 7.0) with higher conductivity and a final wash with citrate buffer at pH 5. The bound antibody was eluted using citrate buffer, pH 2.5 - 3.5.
EXAMPLE 2
Cation exchange chromatography
The eluate obtained from the protein A chromatography procedure described in Example 1 was loaded onto a cation exchange resin (SP Sepharose, VL44x250, 304 mL) pre-equilibrated with Tris buffer (pH 7.5) at a conductivity of 3.0 to 6.0 mS/cm. This was followed by washing the resin with a wash buffer of Tris buffer (pH 7.5) at a conductivity of 3.0 to 6.0 mS/cm. A second wash step was performed with wash buffer consisting of citrate buffer, pH 6.5, at a conductivity of 3.0 to 6.0. The bound antibody was eluted using a buffer of citrate buffer, pH 6.5 at conductivity between 9-12 mS/cm.
EXAMPLE 3
Anion exchange chromatography
The eluate obtained from the cation exchange chromatography procedure described in Example 2 was loaded onto an anion exchange resin (Q-Sepharose FF, VL32x250, 80 mL) pre-equilibrated with a Tris buffer (pH 7.5) equilibration buffer. This was followed by a post load wash with equilibration buffer and the load and wash flow-through was collected.
Table 1 :
BDL: Below Detection Limit
Table 2:
K0: Species devoid of the C-terminal lysine residue
BDL: Below Detection Limit

Claims

1. A process for purification of an antibody, comprising, a) loading the antibody containing solution onto a cation exchange chromatography support at a particular pH
b) washing the support with a first wash buffer at a pH similar to the pH of the load buffer
c) washing the support with a second wash buffer at a second pH and
d) eluting the antibody from the support with an elution buffer at a pH similar to the second wash buffer,
wherein the pH of the two wash buffers are greater than 6.
2. A process according to claim 1 , wherein the pH value of the first wash buffer is from about pH 6.0 to about pH 8.0
3. A process according to claim 2, wherein the pH value is from about pH 6.5 to about pH 7.5.
4. A process according to claim 3, wherein the pH value is about pH 7.5.
5. A process according to claim 1 , wherein the pH value of the second wash buffer is about 6.5.
6. A process according to claim 1 , wherein the pH value of the elution buffer is about 6.5.
7. A process according to claim 1 , wherein the cation-exchange
chromatography is preceded by a protein-A affinity chromatography step.
8. A process according to claim 1 , wherein the cation-exchange
chromatography is preceded by an anion exchange chromatography step or a hydrophobic interaction chromatography step.
9. A process according to claim 1 , wherein the cation- exchange
chromatography step is followed by an anion exchange chromatography step or a hydrophobic interaction chromatography step.
10. A process according to claim 1 , wherein the cation- exchange chromatography step is preceded and/or followed by one or more ion exchange chromatography steps.
EP12790188.2A 2011-05-26 2012-05-24 Purification of anti-cd20 antibodies Not-in-force EP2714713B1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN1783CH2011 2011-05-26
PCT/IB2012/052594 WO2012160530A1 (en) 2011-05-26 2012-05-24 Purification of antibodies

Publications (3)

Publication Number Publication Date
EP2714713A1 true EP2714713A1 (en) 2014-04-09
EP2714713A4 EP2714713A4 (en) 2014-10-29
EP2714713B1 EP2714713B1 (en) 2018-05-09

Family

ID=47216681

Family Applications (1)

Application Number Title Priority Date Filing Date
EP12790188.2A Not-in-force EP2714713B1 (en) 2011-05-26 2012-05-24 Purification of anti-cd20 antibodies

Country Status (3)

Country Link
US (1) US20140107321A1 (en)
EP (1) EP2714713B1 (en)
WO (1) WO2012160530A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014118685A2 (en) * 2013-01-29 2014-08-07 Dr. Reddy's Laboratories Limited Method of altering the acidic variant content of antibody
WO2019183334A1 (en) 2018-03-21 2019-09-26 Waters Technologies Corporation Non-antibody high-affinity-based sample preparation, sorbents, devices and methods
EP3643322A1 (en) * 2018-10-26 2020-04-29 Mabion SA Low aggregate anti cd20 ligand formulation

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0752248T3 (en) 1992-11-13 2000-11-13 Idec Pharma Corp Therapeutic use of chimeric and radiolabeled antibodies against human B lymphocyte restricted differentiation antibody
WO2001032878A2 (en) * 1999-11-04 2001-05-10 University College London A novel polypeptide hormone phosphatonin
US6593123B1 (en) * 2000-08-07 2003-07-15 Avigen, Inc. Large-scale recombinant adeno-associated virus (rAAV) production and purification
HUE033623T2 (en) * 2002-09-11 2017-12-28 Genentech Inc Protein purification
CN102887955A (en) * 2006-04-05 2013-01-23 艾博特生物技术有限公司 Purified antibody composition
ES2533266T5 (en) * 2007-10-30 2018-04-18 Genentech, Inc. Purification of antibodies by cation exchange chromatography
US20120177640A1 (en) * 2009-07-24 2012-07-12 Josef Burg Optimizing the production of antibodies
EP2480561B1 (en) * 2009-09-23 2016-07-13 E. R. Squibb & Sons, L.L.C. Cation exchange chromatography

Also Published As

Publication number Publication date
EP2714713B1 (en) 2018-05-09
WO2012160530A1 (en) 2012-11-29
US20140107321A1 (en) 2014-04-17
EP2714713A4 (en) 2014-10-29

Similar Documents

Publication Publication Date Title
US20130178608A1 (en) Protein purification by ion exchange
US12157073B2 (en) Use of alkaline washes during chromatography to remove impurities
EP2480561B1 (en) Cation exchange chromatography
WO2012160536A1 (en) Antibody purification
US20200283472A1 (en) A process for purification of fc-fusion proteins
WO2013009526A1 (en) Method for purifying fc-fusion protein
WO2013158279A1 (en) Protein purification methods to reduce acidic species
MX2009002014A (en) Process for the purification of fc-containing proteins.
US20180094023A1 (en) Method for separation of monomeric polypeptides from aggregated polypeptides
US20140128577A1 (en) Purification of chimeric protein
CN112313248A (en) Method for purifying monomeric monoclonal antibodies
US20130116413A1 (en) Purification of proteins
US20210054024A1 (en) Use of caprylic acid precipitation for protein purification
EP2714713B1 (en) Purification of anti-cd20 antibodies
WO2014102814A1 (en) Process for the purification of fc fusion proteins
Zhao et al. Applications of ion-exchange chromatography for the purification of antibodies
CN101535335A (en) Process for the purification of Fc-containing proteins
WO2013054250A1 (en) Purification method
KR20230132470A (en) Protein compositions and methods of producing and using them

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20131216

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20141001

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/16 20060101ALI20140926BHEP

Ipc: C07K 1/18 20060101AFI20140926BHEP

Ipc: C07K 1/20 20060101ALI20140926BHEP

Ipc: C07K 16/00 20060101ALI20140926BHEP

Ipc: C07K 1/22 20060101ALI20140926BHEP

Ipc: C07K 16/28 20060101ALI20140926BHEP

17Q First examination report despatched

Effective date: 20170206

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Ref document number: 602012046212

Country of ref document: DE

Free format text: PREVIOUS MAIN CLASS: C07K0001140000

Ipc: C07K0001180000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RIC1 Information provided on ipc code assigned before grant

Ipc: C07K 1/16 20060101ALI20171005BHEP

Ipc: C07K 16/28 20060101ALI20171005BHEP

Ipc: C07K 16/00 20060101ALI20171005BHEP

Ipc: C07K 1/20 20060101ALI20171005BHEP

Ipc: A61K 39/395 20060101ALI20171005BHEP

Ipc: C07K 1/22 20060101ALI20171005BHEP

Ipc: C07K 1/18 20060101AFI20171005BHEP

INTG Intention to grant announced

Effective date: 20171109

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

GRAL Information related to payment of fee for publishing/printing deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR3

GRAR Information related to intention to grant a patent recorded

Free format text: ORIGINAL CODE: EPIDOSNIGR71

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20180329

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

Ref country code: AT

Ref legal event code: REF

Ref document number: 997513

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180515

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: DE

Ref legal event code: R096

Ref document number: 602012046212

Country of ref document: DE

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 7

REG Reference to a national code

Ref country code: NL

Ref legal event code: MP

Effective date: 20180509

REG Reference to a national code

Ref country code: LT

Ref legal event code: MG4D

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: NO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180809

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180809

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180810

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: RS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: HR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: AT

Ref legal event code: MK05

Ref document number: 997513

Country of ref document: AT

Kind code of ref document: T

Effective date: 20180509

REG Reference to a national code

Ref country code: BE

Ref legal event code: MM

Effective date: 20180531

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

REG Reference to a national code

Ref country code: DE

Ref legal event code: R097

Ref document number: 602012046212

Country of ref document: DE

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

Ref country code: SM

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

Ref country code: MC

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

26N No opposition filed

Effective date: 20190212

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: BE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180531

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: AL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO

Effective date: 20120524

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180509

Ref country code: MK

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20180509

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20180909

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20220517

Year of fee payment: 11

Ref country code: FR

Payment date: 20220520

Year of fee payment: 11

Ref country code: DE

Payment date: 20220531

Year of fee payment: 11

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602012046212

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20230524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20231201

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230524

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20230531